- |||||||||| STB-C017 / Syntekabio
Journal, IO biomarker: Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway. (Pubmed Central) - Jan 4, 2022
An orally available lead compound, STB-C017 (designated hereafter as STB), effectively inhibited the enzymatic and cellular activity of IDO and TDO in vitro...Notably, STB-based combination immunotherapy elicited the most potent anti-tumor efficacy through concurrent treatment with immune checkpoint inhibitors, leading to complete tumor regression and long-term overall survival. Our study demonstrated that a novel Kyn pathway regulator derived using deep learning technology can activate T cell immunity and potentiate immune checkpoint blockade by overcoming an immunosuppressive TME.
|
